This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.
The technology utilises outer membrane vesicles (OMVs) to deliver antigens, often eliminating the need for adjuvants while triggering the immune response. Can pharma tariffs “Make America Manufacture Again”?
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP), an immune-mediated neuromuscular disorder of the peripheral nervous system. Can pharma tariffs “Make America Manufacture Again”?
This integration will reinforce Juvenescence’s pipeline in cardio-metabolism, cognition, immunity and cellular repair sectors. Can pharma tariffs “Make America Manufacture Again”? Incorporating Ro5’s AI platform into Juvenescence is expected to accelerate the development of AI-enabled treatments.
June 23, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook HBM7020 activates immune system T cells to target and destroy B cells and plasma cells involved in many autoimmune diseases. Can pharma tariffs “Make America Manufacture Again”? Credit: luchschenF /Shutterstock.
July 22, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook PsO is an immune-mediated disease characterised by rapid skin cell proliferation leading to inflamed plaques that can cause discomfort or pain. Credit: design_cam/Shutterstock.com.
Vertex was also developing a version of the therapy called VX-264 in which the cells were encapsulated in a protective device designed to protect them from rejection by the immune system, but that failed to hit the mark in early clinical testing and has been dropped.
The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock.
Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. Can pharma tariffs “Make America Manufacture Again”? Data Insights The gold standard of business intelligence.
It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity.
A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62
The biotech used these funds to establish a pipeline that includes three metabolic disease programmes, with further assets across immune disorders and endocrine diseases. Can pharma tariffs “Make America Manufacture Again”? Apple Tree Partners founded the Deep Apple in 2022, investing $52m in series A funding.
Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Reports LOA and PTSR Model - Immune Globulin (Human) in Chronic Lymphocytic. Data Insights The gold standard of business intelligence.
CD4+T-cells and lymphocytes are both crucial elements of the immune system. Can pharma tariffs “Make America Manufacture Again”? Low levels of either increase the likelihood of infections and other health problems. HIV itself can reduce CD4 count – a value lower than 200 indicates acquired immunodeficiency syndrome (AIDS).
A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).
fired 17 sitting members of the Advisory Committee on Immunization Practices at the Centers for Disease Control and Prevention (CDC), concerns rose about the stance of federal agencies on vaccines. Can pharma tariffs “Make America Manufacture Again”?
Its design minimises interaction with Fc-gamma (Fcγ) receptors on macrophages, enhancing the ability of the body’s immune cells to recognise and combat tumours.
Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Can pharma tariffs “Make America Manufacture Again”? Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.”
LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?
Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Find out more Sign up for our daily news round-up!
LEO’s new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. It has also been approved in expanded indications in GPP in certain territories.
This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. Can pharma tariffs “Make America Manufacture Again”?
Climb Bio is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, and Brennan talks about the potential of B-cell depletion therapies, as well as the challenges and opportunities in developing novel biotechnology.
The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.
By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape. Can pharma tariffs “Make America Manufacture Again”?
RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Can pharma tariffs “Make America Manufacture Again”?
In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety. Can pharma tariffs “Make America Manufacture Again”?
Breaking into that could be a challenge for Nektar, but the company said in a statement that the rapid improvement in EASI scores and reduction of itch in REZOLVE-AD "show potential differentiation of this novel regulatory T-cell mechanism as a first and best-in-class immune-modulator."
A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Can pharma tariffs “Make America Manufacture Again”? Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.
The drug is being evaluated as both a monotherapy and in combination with Merck & Co’s Keytruda (pembrolizumab) for cancers such as melanoma, after demonstrating tumour regression, enhanced T-cell infiltration, and durable immune memory in preclinical studies. This field is required.
From dissecting clinical updates to identifying novel targets beyond NLRP3, this summit brings together the brightest minds transforming the field of innate immunity and inflammation.
Partner Content Partner Content Unlocking the Potential of Targeting the Innate Immune Syste. Finding the right chemical start points is crucial to help you save time and costs in the long run. At BIO 2025 in Boston, editor-in-chief Jonah Comstock spoke with Dr Raza Bokhari, CEO of Medicus Pharma. Medical affairs is evolving.
In 1980, Life and Time magazines introduced America to a new cancer wonder drug: interferon, a protein ripped from the body’s own immune system that showed exciting early results, before ultimately proving both too impotent and too toxic to be useful beyond a couple of malignancies.
The post QS-21, the ‘Gold Standard’ of immune system activators used in Covid-19 and other vaccines to be presented by CEO Gaston Salinas at BIO CEO & Investor Conference appeared first on Pharma Mirror Magazine. Salinas will also address additional issues of quality, cost and the sizeable environmental.
This is because they often have weaker immune systems, so they can’t fight off a viral infection easily. appeared first on Pharma Mirror Magazine. Researchers have found that the elderly are particularly susceptible to the COVID-19 virus that caused the epidemic. This new situation puts.
While the covid19 pandemic showed us just how important physical health and a robust immune system are, the news of the war is quickly showing us the importance of mental well-being. The post 8 Effective Ways To Enhance Your Health In 2022 appeared first on Pharma Mirror Magazine.
Studied by NOV and Eutilex with humanized mice, EU101(NOV1801), effectively eradicated human tumors and showed synergistic anti-tumor activity with immune checkpoint blockade. The post Samsung Biologics, National OncoVenture, and Eutilex obtains IND Approval from FDA appeared first on Pharma Mirror Magazine. We are extremely glad to.
Pan-JAK inhibitors have been developed and tested in clinical trials, approved and commercialised for many different indications but mainly for the treatment of chronic inflammatory conditions associated with an overactive immune response. VR588 was previously developed by Vectura as part of its former speciality pharma pipeline.
It also addresses the question of whether or not the presence of antibodies confers immunity to SARS-CoV-2, and makes recommendations on information to give to patients who have tested positive or negative. The post FIP expert group issues advice for pharmacists on COVID-19 tests appeared first on Pharma Mirror Magazine.
The collaboration aims to build on a proprietary immune-based treatment for chronic inflammatory conditions being developed by Dr. John Foerster’s team at the University of Dundee. The goal of the partnership is to fully control the itch associated with skin conditions and achieve a prolonged and deep therapeutic effect for patients.
The post Almirall and IRB Barcelona announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases appeared first on Pharma Mirror Magazine.
Preliminary data from prior small studies had suggested a potential benefit of interferon beta-1a, a natural antiviral component of the immune system, for COVID-19 patients. The post Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19 appeared first on Pharma Mirror Magazine.
today announced that both parties have entered into a research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders including Alzheimer’s disease (AD) which modulate immune competence in neurons and glia cells. Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co.,
The concept of pre-emptively training the immune system to increase the frequencies of tumour-reactive T cells could be game-changing for cancer patients worldwide. For years, the promise of therapeutic cancer vaccines has intrigued researchers working in the oncology space. And for good reason.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content